TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment of Metastatic or Recurrent Urethral Cancer
Source: Urethral Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: July 19, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Local recurrences of urethral cancer may be amenable to local modality therapy with radiation or surgery, with or without chemotherapy. For more information, see the Treatment Option Overview for Urethral Cancer section. Metastatic disease may be treated with regimens in common use for other urothelial transitional cell or squamous cell carcinomas, or anal carcinomas, depending on the histology.[1-3]
Source links and citations
Treatment options for metastatic or recurrent urethral cancer include the following:
Surgical excision of locally recurrent urethral cancer after radiation therapy should be considered, if feasible.
Combination radiation therapy and wider surgical resection should be considered for locally recurrent urethral cancer after surgery alone.
Clinical trials using chemotherapy should be considered for metastatic urethral cancer. Transitional cell cancer of the urethra may respond favorably to the same chemotherapy regimens used for advanced transitional cell cancer of the bladder.[1-4]
The level of evidence for these treatment options is Level of evidence C3.
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice